An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease

Last updated: July 10, 2024
Sponsor: Affiliated Hospital of Jiangnan University
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Cervical Lymphovenous Bypass: Lymphaticovenous end-to-side anastomosis

Deep cervical Lymphovenous Bypass

Clinical Study ID

NCT06448975
19691027
  • Ages 60-80
  • All Genders

Study Summary

The main pathological mechanism of Alzheimer's Disease (AD) is the abnormal deposition of amyloid-beta (Aβ) and tau proteins in the brain. Recent studies indicate that these two proteins are primarily cleared through the glymphatic system-meningeal lymphatic vessels-deep cervical lymphatic vessels pathway. Lymphatic circulation disorders in elderly patients can directly lead to the abnormal deposition of these proteins. Deep cervical lymphovenous bypass can improve lymphatic circulation and effectively treat lymphedema. This project aims to verify the effectiveness of 'deep cervical lymphovenous bypass' in treating AD, offering a new surgical treatment method to improve cognitive impairment and the quality of life for AD patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. The age ranged from 60 to 80 years, and the time from initial diagnosis toenrollment was more than 12 months

  2. The estimated survival time is more than 12 months;

  3. The clinically diagnosed patients with mild to severe Alzheimer's Disease;

  4. The imaging examination has the correlation diagnosis evidence;

  5. Volunteer to participate in the project and sign an informed consent form with theguardian.

Exclusion

Exclusion Criteria:

  1. Complicated with other severe systemic underlying diseases;

  2. Unable to tolerate general anesthesia;

  3. The pregnant women;

  4. Recent severe infection or infectious diseases within 4 weeks;

  5. Unable to complete the evaluator or refused to complete the one-year clinicalfollow-up.

  6. Refusal to participate

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Cervical Lymphovenous Bypass: Lymphaticovenous end-to-side anastomosis
Phase:
Study Start date:
May 31, 2024
Estimated Completion Date:
July 01, 2026

Study Description

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that insidiously begins. Clinically characterized by memory impairment, aphasia, apraxia, agnosia, and other symptoms, it poses a severe threat to the quality of life of the elderly and brings a heavy burden to society and families. To date, there are no effective methods to prevent, halt, or cure AD. Therefore, there is an urgent need to explore new treatment approaches.

The definition of the glymphatic system and the discovery of meningeal lymphatic vessels (MLV) have overturned the traditional view of the immune privilege of the central nervous system, offering new clues and hope for the study and treatment of many brain diseases, including AD. The main pathological mechanism of Alzheimer's Disease (AD) is the abnormal deposition of amyloid-beta (Aβ) and tau proteins in the brain. Recent research indicates that these two proteins are primarily cleared through the glymphatic system-meningeal lymphatic vessels-deep cervical lymphatic vessels pathway, and lymphatic circulation disorders in elderly patients can directly lead to the abnormal deposition of these proteins. Deep cervical lymphovenous bypass can improve lymphatic circulation and effectively treat lymphedema. This project aims to verify the effectiveness of 'deep cervical lymphovenous bypass' in treating AD, providing a new surgical method to improve cognitive impairment and the quality of life for AD patients.

Connect with a study center

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.